| pubmed-article:6102839 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:6102839 | lifeskim:mentions | umls-concept:C0001645 | lld:lifeskim |
| pubmed-article:6102839 | lifeskim:mentions | umls-concept:C0009014 | lld:lifeskim |
| pubmed-article:6102839 | lifeskim:mentions | umls-concept:C1704675 | lld:lifeskim |
| pubmed-article:6102839 | pubmed:issue | 3 | lld:pubmed |
| pubmed-article:6102839 | pubmed:dateCreated | 1980-6-25 | lld:pubmed |
| pubmed-article:6102839 | pubmed:abstractText | On the hypothesis that non-selective beta-blockers can antagonize or reverse the antihypertensive effect of clonidine (C), 12 hypertensive outpatients were treated with C alone and in combination with propranolol (P), atenolol (A) and prazosin (Pz). C alone (0.11 or 0.22 mg b.i.d.) or in combination with P (80 mg b.i.d.) did not provide normotension. Changing P to A (50 mg b.i.d.) reduced supine systolic and diastolic pressures, which now were significantly lower (p less than 0.01) than during C alone. Changing A to P again resulted in elevated pressures. Pz (1 mg t.i.d.) added to the C+P regimen lowered supine blood pressures to the levels otherwise recorded during C+A. C dose-dependently contracted rabbit aortic spiral in vitro, reaching about 50% of maximum responses to noradrenaline. Pz abolished this response. P (0.1--10 micrograms/ml) but not A somewhat enhanced responses to high doses of C. Sotalol rather antagonized C contractions. We conclude that A but not P enhances the antihypertensive action of C. No hypertensive interaction was observed. | lld:pubmed |
| pubmed-article:6102839 | pubmed:language | eng | lld:pubmed |
| pubmed-article:6102839 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6102839 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:6102839 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6102839 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6102839 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6102839 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6102839 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6102839 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6102839 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:6102839 | pubmed:issn | 0001-6101 | lld:pubmed |
| pubmed-article:6102839 | pubmed:author | pubmed-author:MattilaM JMJ | lld:pubmed |
| pubmed-article:6102839 | pubmed:author | pubmed-author:JounelaA JAJ | lld:pubmed |
| pubmed-article:6102839 | pubmed:author | pubmed-author:JuustilaHH | lld:pubmed |
| pubmed-article:6102839 | pubmed:author | pubmed-author:LiljaMM | lld:pubmed |
| pubmed-article:6102839 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:6102839 | pubmed:volume | 207 | lld:pubmed |
| pubmed-article:6102839 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:6102839 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:6102839 | pubmed:pagination | 173-6 | lld:pubmed |
| pubmed-article:6102839 | pubmed:dateRevised | 2007-11-15 | lld:pubmed |
| pubmed-article:6102839 | pubmed:meshHeading | pubmed-meshheading:6102839-... | lld:pubmed |
| pubmed-article:6102839 | pubmed:meshHeading | pubmed-meshheading:6102839-... | lld:pubmed |
| pubmed-article:6102839 | pubmed:meshHeading | pubmed-meshheading:6102839-... | lld:pubmed |
| pubmed-article:6102839 | pubmed:meshHeading | pubmed-meshheading:6102839-... | lld:pubmed |
| pubmed-article:6102839 | pubmed:meshHeading | pubmed-meshheading:6102839-... | lld:pubmed |
| pubmed-article:6102839 | pubmed:meshHeading | pubmed-meshheading:6102839-... | lld:pubmed |
| pubmed-article:6102839 | pubmed:meshHeading | pubmed-meshheading:6102839-... | lld:pubmed |
| pubmed-article:6102839 | pubmed:meshHeading | pubmed-meshheading:6102839-... | lld:pubmed |
| pubmed-article:6102839 | pubmed:meshHeading | pubmed-meshheading:6102839-... | lld:pubmed |
| pubmed-article:6102839 | pubmed:meshHeading | pubmed-meshheading:6102839-... | lld:pubmed |
| pubmed-article:6102839 | pubmed:meshHeading | pubmed-meshheading:6102839-... | lld:pubmed |
| pubmed-article:6102839 | pubmed:meshHeading | pubmed-meshheading:6102839-... | lld:pubmed |
| pubmed-article:6102839 | pubmed:meshHeading | pubmed-meshheading:6102839-... | lld:pubmed |
| pubmed-article:6102839 | pubmed:meshHeading | pubmed-meshheading:6102839-... | lld:pubmed |
| pubmed-article:6102839 | pubmed:meshHeading | pubmed-meshheading:6102839-... | lld:pubmed |
| pubmed-article:6102839 | pubmed:meshHeading | pubmed-meshheading:6102839-... | lld:pubmed |
| pubmed-article:6102839 | pubmed:meshHeading | pubmed-meshheading:6102839-... | lld:pubmed |
| pubmed-article:6102839 | pubmed:year | 1980 | lld:pubmed |
| pubmed-article:6102839 | pubmed:articleTitle | Interaction of clonidine and beta-blockers. | lld:pubmed |
| pubmed-article:6102839 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:6102839 | pubmed:publicationType | Clinical Trial | lld:pubmed |
